SEGMENT AND GEOGRAPHIC INFORMATION (Tables)
|
9 Months Ended |
Sep. 30, 2022 |
| Segment Reporting [Abstract] |
|
| Schedule of Net Sales and Profit by Segments |
Net sales and profit by each reportable segment for the three and nine months ended September 30, 2022 and 2021 are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | Dollars in thousands | 2022 | | 2021 | | 2022 | | 2021 | | Segment Net Sales | | | | | | | | | Codman Specialty Surgical | $ | 249,796 | | | $ | 256,497 | | | $ | 754,967 | | | $ | 754,575 | | Tissue Technologies | 135,395 | | | 130,364 | | | 404,677 | | | 382,349 | | | Total revenues | $ | 385,191 | | | $ | 386,861 | | | $ | 1,159,644 | | | $ | 1,136,924 | | | Segment Profit | | | | | | | | | Codman Specialty Surgical | $ | 105,717 | | | $ | 110,686 | | | $ | 308,073 | | | $ | 331,460 | | Tissue Technologies | 59,754 | | | 57,730 | | | 175,273 | | 172,154 | | | Segment profit | 165,471 | | | 168,416 | | | 483,346 | | | 503,614 | | | Amortization | (3,141) | | (4,113) | | (10,339) | | | (12,838) | | Corporate and other | (97,281) | | | (107,864) | | | (301,927) | | (351,769) | | Operating income | $ | 65,049 | | | $ | 56,439 | | | $ | 171,080 | | | $ | 139,007 | | Total revenue by major geographic area consisted of the following: | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | Dollars in thousands | 2022 | | 2021 | | 2022 | | 2021 | | United States | $ | 282,016 | | | $ | 275,775 | | | $ | 832,714 | | | $ | 801,754 | | | Europe | 38,301 | | | 46,458 | | | 128,907 | | | 140,714 | | | Asia Pacific | 42,774 | | | 45,015 | | | 133,856 | | | 136,616 | | | Rest of World | 22,100 | | | 19,613 | | | 64,167 | | | 57,840 | | | Total Revenues | $ | 385,191 | | | $ | 386,861 | | | $ | 1,159,644 | | | $ | 1,136,924 | |
|
| Schedule of Geographic Revenue by Area |
Net sales and profit by each reportable segment for the three and nine months ended September 30, 2022 and 2021 are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | Dollars in thousands | 2022 | | 2021 | | 2022 | | 2021 | | Segment Net Sales | | | | | | | | | Codman Specialty Surgical | $ | 249,796 | | | $ | 256,497 | | | $ | 754,967 | | | $ | 754,575 | | Tissue Technologies | 135,395 | | | 130,364 | | | 404,677 | | | 382,349 | | | Total revenues | $ | 385,191 | | | $ | 386,861 | | | $ | 1,159,644 | | | $ | 1,136,924 | | | Segment Profit | | | | | | | | | Codman Specialty Surgical | $ | 105,717 | | | $ | 110,686 | | | $ | 308,073 | | | $ | 331,460 | | Tissue Technologies | 59,754 | | | 57,730 | | | 175,273 | | 172,154 | | | Segment profit | 165,471 | | | 168,416 | | | 483,346 | | | 503,614 | | | Amortization | (3,141) | | (4,113) | | (10,339) | | | (12,838) | | Corporate and other | (97,281) | | | (107,864) | | | (301,927) | | (351,769) | | Operating income | $ | 65,049 | | | $ | 56,439 | | | $ | 171,080 | | | $ | 139,007 | | Total revenue by major geographic area consisted of the following: | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | Dollars in thousands | 2022 | | 2021 | | 2022 | | 2021 | | United States | $ | 282,016 | | | $ | 275,775 | | | $ | 832,714 | | | $ | 801,754 | | | Europe | 38,301 | | | 46,458 | | | 128,907 | | | 140,714 | | | Asia Pacific | 42,774 | | | 45,015 | | | 133,856 | | | 136,616 | | | Rest of World | 22,100 | | | 19,613 | | | 64,167 | | | 57,840 | | | Total Revenues | $ | 385,191 | | | $ | 386,861 | | | $ | 1,159,644 | | | $ | 1,136,924 | |
|